Author:
Rubio-Briones J.,Borque A.,Esteban L.M.,Iborra I.,López P.A.,Gil J.M.,Pallás Y.,Fumadó Ll.,Martínez-Breijo S.,Chantada V.,Gómez E.,Quicios C.,Congregado C.B.,Medina R.,Ortiz M.,Montesino M.,Clar F.,Soto J.,Campá J.M.
Reference24 articles.
1. Mottet N, Bellmunt J, Briers E, van den Bergh RCN, Bolla M, van Casteren NJ, et al. Guidelines on prostate cancer, v.2015 [consultado 1 May 2015]. Disponible en: http://uroweb.org/guideline/prostate-cancer/
2. Prostate testing for cancer and treatment (ProtecT) feasibility study;Donovan;Health Technol Assess,2003
3. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening;Savage;Cancer Epidemiol Biomarkers Prev,2010
4. Registro nacional del cáncer de próstata en España;Cózar;Actas Urol Esp,2013
5. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer;Klotz;J Clin Oncol,2015
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献